Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and
anti-tumor activities of abiraterone acetate (also referred to as CB7630) in patients with
hormone refractory prostate cancer (HRPC).